March 12, 2012
Nippon Shinyaku and Taiho Pharmaceutical announced on March 9 that they have agreed to cancel a licensing agreement for the joint development and marketing of the novel antipruritic agent NST-141 (development code), because a clear antipruritic effect could not be...read more